Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ann Oncol
Main Authors: Knox, J J, Barrios, C H, Kim, T M, Cosgriff, T, Srimuninnimit, V, Pittman, K, Sabbatini, R, Rha, S Y, Flaig, T W, Page, R D, Beck, J T, Cheung, F, Yadav, S, Patel, P, Geoffrois, L, Niolat, J, Berkowitz, N, Marker, M, Chen, D, Motzer, R J
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2018
Teme:
Corrigenda
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6290878/
https://ncbi.nlm.nih.gov/pubmed/29390043
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx807
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki